title: High reinfection rate and treatment failures in children treated with amodiaquine for falciparum malaria in Muheza villages, Northeastern Tanzania.
abstract: In May 2003, we studied amodiaquine (AQ) efficacy in children < 5 years of age with uncomplicated falciparum malaria in Magoda and Mpapayu (with insecticide treated nets [ITNs]) and Mgome (without ITNs) in Muheza, Tanzania. The trial involved 28 days of follow-up, and data were adjusted by polymerase chain reaction (PCR) genotyping of msp1 and msp2 genes. Additionally, Pfcrt codon 72-76 polymorphisms were studied by PCR and sequence-specific oligonucleotide probe (SSOP) ELISA. In 54 cases with complete follow-up, a significant difference in late treatment failure (LTF) rates was seen (60.7% in ITN versus 88.5% in non-ITN villages, P = 0.02) before PCR correction. However, after PCR correction, 23 cases (60.5%) were confirmed as reinfections, giving a true LTF rate of 21.4% (6/28) and 34.6% (9/26) in the above settings, respectively. Frequency of Pfcrt CVIET haplotype mutation pretreatment was high (97.0%); the remaining samples were CVMNK. We conclude that AQ alone is no longer effective in the study area.
authors.affiliation: National Institute for Medical Research, Tanga Centre, Tanga, Tanzania. marthalemnge@yahoo.com
authors.forename: Martha
authors.initials: M
authors.lastname: Lemnge
authors.forename: Michael
authors.initials: M
authors.lastname: Alifrangis
authors.forename: Mwanaidi Y
authors.initials: MY
authors.lastname: Kafuye
authors.forename: Method D
authors.initials: MD
authors.lastname: Segeja
authors.forename: Samwel
authors.initials: S
authors.lastname: Gesase
authors.forename: Daniel
authors.initials: D
authors.lastname: Minja
authors.forename: Julius J
authors.initials: JJ
authors.lastname: Massaga
authors.forename: Anita M
authors.initials: AM
authors.lastname: Rønn
authors.forename: Ib C
authors.initials: IC
authors.lastname: Bygbjerg
mesh_terms: D000655:Amodiaquine / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D000962:Antimalarials / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D002675:Child, Preschool; D015331:Cohort Studies; D006239:Haplotypes; D006400:Hematocrit; D006801:Humans; D007223:Infant; D016778:Malaria, Falciparum / Q000188:drug therapy* / Q000453:epidemiology; D008565:Membrane Proteins / Q000235:genetics; D026901:Membrane Transport Proteins; D010963:Plasmodium falciparum / Q000187:drug effects* / Q000302:isolation & purification; D016133:Polymerase Chain Reaction / Q000379:methods; D015995:Prevalence; D015800:Protozoan Proteins; D012008:Recurrence; D013636:Tanzania / Q000453:epidemiology; D017211:Treatment Failure
chemical_list: D000962:Antimalarials; D008565:Membrane Proteins; D026901:Membrane Transport Proteins; C416369:PfCRT protein, Plasmodium falciparum; D015800:Protozoan Proteins; D000655:Amodiaquine